DI DESIDERO, TERESA Statistiche
DI DESIDERO, TERESA
DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE
Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma
2020-01-01 Orlandi, Paola; Banchi, Marta; Alì, Greta; Di Desidero, Teresa; Fini, Elisabetta; Fontanini, Gabriella; Bocci, Guido
Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward
2015-01-01 Lazzeri, Stefano; Ripandelli, Guido; Sartini, Maria Sole; Parravano, Mariacristina; Varano, Monica; Nardi, Marco; DI DESIDERO, Teresa; Orlandi, Paola; Bocci, Guido
Agenti melanocortinici per l’impiego nel trattamento terapeutico del melanoma, dei tumori del tratto gastroenterico e del carcinoma tiroideo
2018-01-01 Bocci, G; Di Desidero, T; Giuliani, D; Guarini, S; Orlandi, P; Ottani, A; Pardini, C; Vaglini, F
Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer
2014-01-01 Cruz-Muñoz, William; Di Desidero, Teresa; Man, Shan; Xu, Ping; Jaramillo, Maria Luz; Hashimoto, Kae; Collins, Catherine; Banville, Myriam; O'Connor-Mccourt, Maureen D.; Kerbel, Robert S.
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells
2011-01-01 Bocci, Guido; Fioravanti, Anna; LA MOTTA, Concettina; Orlandi, Paola; Canu, B.; DI DESIDERO, Teresa; Mugnaini, L.; Sartini, S.; Cosconati, S.; Frati, R.; Antonelli, Alessandro; Berti, Piero; Miccoli, Paolo; DA SETTIMO PASSETTI, Federico; Danesi, Romano
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1.
2013-01-01 DI DESIDERO, Teresa; Fioravanti, Anna; Orlandi, Paola; B., Canu; Giannini, Riccardo; Borrelli, Nicla; S., Man; P., Xu; Fontanini, Gabriella; Basolo, Fulvio; R. S., Kerbel; G., Francia; Danesi, Romano; Bocci, Guido
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy
2018-01-01 Pasqualetti, Francesco; Gonnelli, Alessandra; Cantarella, Martina; Delishaj, Durim; Molinari, Alessandro; Ortenzi, Valerio; Carbone, Francesco; Montrone, Sabrina; Ursino, Stefano; Franceschi, Sara; Morganti, Riccardo; Orlandi, Paola; DI DESIDERO, Teresa; Mazzanti, CHIARA MARIA; Zavaglia, Katia; Naccarato, ANTONIO GIUSEPPE; Bocci, Guido; Paiar, Fabiola
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics
2019-01-01 Di Desidero, Teresa; Orlandi, Paola; Fioravanti, Anna; Alì, Greta; Cremolini, Chiara; Loupakis, Fotios; Gentile, Daniela; Banchi, Marta; Cucchiara, Federico; Antoniotti, Carlotta; Masi, Gianluca; Fontanini, Gabriella; Falcone, Alfredo; Bocci, Guido
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients
2010-01-01 Loupakis, F.; Cremolini, Chiara; Fioravanti, A.; Lupi, C.; Ferrarini, I.; Orlandi, P.; Sensi, E.; Canu, B.; Salvatore, L.; Schirripa, M.; Fornaro, L.; DI DESIDERO, T.; Baldi, G.; Giannini, R.; Masi, G.; Basolo, F.; Fontanini, Gabriella; Danesi, Romano; Bocci, Guido; Falcone, Alfredo
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients
2010-01-01 Loupakis, F.; Cremolini, Chiara; Fioravanti, A.; Lupi, C.; Ferrarini, I.; Orlandi, P.; Sensi, E.; Canu, B.; Salvatore, L.; DI DESIDERO, T.; Masi, G.; Fontanini, Gabriella; Danesi, Romano; Bocci, Guido; Falcone, Alfredo
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial.
2013-01-01 Cremolini, Chiara; Loupakis, F; Bocci, Guido; Fioravanti, A; Masi, G; Salvatore, L; Marmorino, F; Orlandi, P; Schirripa, M; DI DESIDERO, T; Antoniotti, C; Canu, B; Danesi, Romano; Falcone, Alfredo
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial.
2013-01-01 Antoniotti, C; Loupakis, F; Cremolini, Chiara; Bocci, Guido; Fioravanti, A; Masi, G; Salvatore, L; Marmorino, F; Orlandi, P; Schirripa, M; Bergamo, F; Zoratto, F; DI DESIDERO, T; Canu, B; Danesi, Romano; Falcone, Alfredo
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients
2016-01-01 DI DESIDERO, Teresa; Derosa, Lisa; Galli, Luca; Orlandi, Paola; Fontana, Andrea; Fioravanti, Anna; Marconcini, Riccardo; Giorgi, Mario; Campi, Beatrice; Saba, Alessandro; Lucchesi, Sara; Felipetto, Renato; Danesi, Romano; Francia, Giulio; Allegrini, Giacomo; Falcone, Alfredo; Bocci, Guido
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo
2014-01-01 Antonelli, A; Bocci, G; Fallahi, P; La Motta, C; Ferrari, S; Mancusi, C; Fioravanti, A; Di Desidero, T; Sartini, S; Corti, A; Piaggi, S; Materazzi, G; Spinelli, C; Fontanini, G; Danesi, R; Da Settimo, F; Miccoli, P
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo
2012-01-01 Antonelli, Alessandro; Bocci, Guido; LA MOTTA, Concettina; Ferrari, Sm; Fallahi, P; Ruffilli, I; Di Domenicantonio, A; Fioravanti, A; Sartini, S; Minuto, M; Piaggi, Simona; Corti, Alessandro; Alì, G; Di Desidero, T; Berti, Piero; Fontanini, Gabriella; Danesi, Romano; DA SETTIMO PASSETTI, Federico; Miccoli, Paolo
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients
2014-01-01 Derosa, L; Galli, L; Orlandi, Paola; Fioravanti, Anna; DI DESIDERO, Teresa; Fontana, A; Antonuzzo, A; Biasco, E; Farnesi, A; Marconcini, R; Francia, G; Danesi, Romano; Falcone, Alfredo; Bocci, Guido
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation
2019-01-01 Quattrini, Luca; Coviello, Vito; Sartini, Stefania; Di Desidero, Teresa; Orlandi, Paola; Ke, Yi-Yu; Liu, Kai-Lun; Hsieh, Hsing-Pang; Bocci, Guido; La Motta, Concettina
Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
2019-01-01 Di Desidero, Teresa; Orlandi, Paola; Gentile, Daniela; Bocci, Guido
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV)
2010-01-01 Cremolini, Chiara; Loupakis, F.; Salvatore, L.; Fioravanti, A.; Schirripa, M.; Orlandi, P.; Masi, G.; DI DESIDERO, T.; Fornaro, L.; Canu, B.; Baldi, G.; Stasi, I.; Danesi, Romano; Bocci, Guido; Falcone, Alfredo
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV)
2010-01-01 Cremolini, Chiara; Loupakis, F.; Salvatore, L.; Fioravanti, A.; Schirripa, M.; Orlandi, P.; Masi, G.; DI DESIDERO, T.; Fornaro, L.; Canu, B.; Baldi, G.; Stasi, I.; Ferrarini, I.; Ricco, G.; Danesi, Romano; Falcone, Alfredo; Bocci, Guido
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma | 1-gen-2020 | Orlandi, Paola; Banchi, Marta; Alì, Greta; Di Desidero, Teresa; Fini, Elisabetta; Fontanini, Gabriella; Bocci, Guido | |
| Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward | 1-gen-2015 | Lazzeri, Stefano; Ripandelli, Guido; Sartini, Maria Sole; Parravano, Mariacristina; Varano, Monica; Nardi, Marco; DI DESIDERO, Teresa; Orlandi, Paola; Bocci, Guido | |
| Agenti melanocortinici per l’impiego nel trattamento terapeutico del melanoma, dei tumori del tratto gastroenterico e del carcinoma tiroideo | 1-gen-2018 | Bocci, G; Di Desidero, T; Giuliani, D; Guarini, S; Orlandi, P; Ottani, A; Pardini, C; Vaglini, F | |
| Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer | 1-gen-2014 | Cruz-Muñoz, William; Di Desidero, Teresa; Man, Shan; Xu, Ping; Jaramillo, Maria Luz; Hashimoto, Kae; Collins, Catherine; Banville, Myriam; O'Connor-Mccourt, Maureen D.; Kerbel, Robert S. | |
| Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells | 1-gen-2011 | Bocci, Guido; Fioravanti, Anna; LA MOTTA, Concettina; Orlandi, Paola; Canu, B.; DI DESIDERO, Teresa; Mugnaini, L.; Sartini, S.; Cosconati, S.; Frati, R.; Antonelli, Alessandro; Berti, Piero; Miccoli, Paolo; DA SETTIMO PASSETTI, Federico; Danesi, Romano | |
| Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. | 1-gen-2013 | DI DESIDERO, Teresa; Fioravanti, Anna; Orlandi, Paola; B., Canu; Giannini, Riccardo; Borrelli, Nicla; S., Man; P., Xu; Fontanini, Gabriella; Basolo, Fulvio; R. S., Kerbel; G., Francia; Danesi, Romano; Bocci, Guido | |
| Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy | 1-gen-2018 | Pasqualetti, Francesco; Gonnelli, Alessandra; Cantarella, Martina; Delishaj, Durim; Molinari, Alessandro; Ortenzi, Valerio; Carbone, Francesco; Montrone, Sabrina; Ursino, Stefano; Franceschi, Sara; Morganti, Riccardo; Orlandi, Paola; DI DESIDERO, Teresa; Mazzanti, CHIARA MARIA; Zavaglia, Katia; Naccarato, ANTONIO GIUSEPPE; Bocci, Guido; Paiar, Fabiola | |
| Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics | 1-gen-2019 | Di Desidero, Teresa; Orlandi, Paola; Fioravanti, Anna; Alì, Greta; Cremolini, Chiara; Loupakis, Fotios; Gentile, Daniela; Banchi, Marta; Cucchiara, Federico; Antoniotti, Carlotta; Masi, Gianluca; Fontanini, Gabriella; Falcone, Alfredo; Bocci, Guido | |
| Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients | 1-gen-2010 | Loupakis, F.; Cremolini, Chiara; Fioravanti, A.; Lupi, C.; Ferrarini, I.; Orlandi, P.; Sensi, E.; Canu, B.; Salvatore, L.; Schirripa, M.; Fornaro, L.; DI DESIDERO, T.; Baldi, G.; Giannini, R.; Masi, G.; Basolo, F.; Fontanini, Gabriella; Danesi, Romano; Bocci, Guido; Falcone, Alfredo | |
| Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients | 1-gen-2010 | Loupakis, F.; Cremolini, Chiara; Fioravanti, A.; Lupi, C.; Ferrarini, I.; Orlandi, P.; Sensi, E.; Canu, B.; Salvatore, L.; DI DESIDERO, T.; Masi, G.; Fontanini, Gabriella; Danesi, Romano; Bocci, Guido; Falcone, Alfredo | |
| Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. | 1-gen-2013 | Cremolini, Chiara; Loupakis, F; Bocci, Guido; Fioravanti, A; Masi, G; Salvatore, L; Marmorino, F; Orlandi, P; Schirripa, M; DI DESIDERO, T; Antoniotti, C; Canu, B; Danesi, Romano; Falcone, Alfredo | |
| Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial. | 1-gen-2013 | Antoniotti, C; Loupakis, F; Cremolini, Chiara; Bocci, Guido; Fioravanti, A; Masi, G; Salvatore, L; Marmorino, F; Orlandi, P; Schirripa, M; Bergamo, F; Zoratto, F; DI DESIDERO, T; Canu, B; Danesi, Romano; Falcone, Alfredo | |
| Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients | 1-gen-2016 | DI DESIDERO, Teresa; Derosa, Lisa; Galli, Luca; Orlandi, Paola; Fontana, Andrea; Fioravanti, Anna; Marconcini, Riccardo; Giorgi, Mario; Campi, Beatrice; Saba, Alessandro; Lucchesi, Sara; Felipetto, Renato; Danesi, Romano; Francia, Giulio; Allegrini, Giacomo; Falcone, Alfredo; Bocci, Guido | |
| CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo | 1-gen-2014 | Antonelli, A; Bocci, G; Fallahi, P; La Motta, C; Ferrari, S; Mancusi, C; Fioravanti, A; Di Desidero, T; Sartini, S; Corti, A; Piaggi, S; Materazzi, G; Spinelli, C; Fontanini, G; Danesi, R; Da Settimo, F; Miccoli, P | |
| CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo | 1-gen-2012 | Antonelli, Alessandro; Bocci, Guido; LA MOTTA, Concettina; Ferrari, Sm; Fallahi, P; Ruffilli, I; Di Domenicantonio, A; Fioravanti, A; Sartini, S; Minuto, M; Piaggi, Simona; Corti, Alessandro; Alì, G; Di Desidero, T; Berti, Piero; Fontanini, Gabriella; Danesi, Romano; DA SETTIMO PASSETTI, Federico; Miccoli, Paolo | |
| Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients | 1-gen-2014 | Derosa, L; Galli, L; Orlandi, Paola; Fioravanti, Anna; DI DESIDERO, Teresa; Fontana, A; Antonuzzo, A; Biasco, E; Farnesi, A; Marconcini, R; Francia, G; Danesi, Romano; Falcone, Alfredo; Bocci, Guido | |
| Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation | 1-gen-2019 | Quattrini, Luca; Coviello, Vito; Sartini, Stefania; Di Desidero, Teresa; Orlandi, Paola; Ke, Yi-Yu; Liu, Kai-Lun; Hsieh, Hsing-Pang; Bocci, Guido; La Motta, Concettina | |
| Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells | 1-gen-2019 | Di Desidero, Teresa; Orlandi, Paola; Gentile, Daniela; Bocci, Guido | |
| Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) | 1-gen-2010 | Cremolini, Chiara; Loupakis, F.; Salvatore, L.; Fioravanti, A.; Schirripa, M.; Orlandi, P.; Masi, G.; DI DESIDERO, T.; Fornaro, L.; Canu, B.; Baldi, G.; Stasi, I.; Danesi, Romano; Bocci, Guido; Falcone, Alfredo | |
| Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) | 1-gen-2010 | Cremolini, Chiara; Loupakis, F.; Salvatore, L.; Fioravanti, A.; Schirripa, M.; Orlandi, P.; Masi, G.; DI DESIDERO, T.; Fornaro, L.; Canu, B.; Baldi, G.; Stasi, I.; Ferrarini, I.; Ricco, G.; Danesi, Romano; Falcone, Alfredo; Bocci, Guido |